| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maibritt B Andersen, Thomas Werge, Anders Fink-Jense. The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. The Journal of pharmacology and experimental therapeutics. vol 321. issue 3. 2007-07-30. PMID:17374745. |
centrally acting selective muscarinic receptor agonists are currently not available for clinical use, but acetylcholinesterase (ache) inhibitors, which indirectly stimulate achr by blocking the breakdown of acetylcholine by ache, are widely used in the clinic against alzheimer's disease. |
2007-07-30 |
2023-08-12 |
monkey |
| Dayong Wang, Yukihiro Noda, Yuan Zhou, Akihiro Mouri, Hiroyuki Mizoguchi, Atsumi Nitta, Weiduo Chen, Toshitaka Nabeshim. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 6. 2007-07-27. PMID:17133263. |
galantamine, a drug for alzheimer's disease, is a novel cholinergic agent with a dual mode of action, which inhibits acetylcholinesterase and allosterically modulates nicotinic acetylcholine receptors (nachrs), as a result stimulates catecholamine neurotransmission. |
2007-07-27 |
2023-08-12 |
mouse |
| Julia Roensch, Milita Crisby, Agneta Nordberg, Yan Xiao, Lan-Jiang Zhang, Zhi-Zhong Gua. Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochemistry international. vol 50. issue 6. 2007-07-26. PMID:17412455. |
in order to reveal the neuroprotective effects of statins that could be of interest for the prevention and treatment of alzheimer's disease (ad), we investigated the expression of nicotinic acetylcholine receptors (nachrs) detected by rt-pcr, the activity of acetylcholinesterase (ache) and butyrylcholinesterase (buche) by colorimetric determination, and the levels of the alpha-form of secreted beta-amyloid precursor protein (alphaapps) by western blotting in neuroblastoma (sh-sy5y) cells exposed to lovastatin, atorvastatin, rosuvastatin and simvastatin, respectively. |
2007-07-26 |
2023-08-12 |
Not clear |
| Luca Rozzini, Barbara Vicini Chilovi, Erik Bertoletti, Marco Trabucchi, Alessandro Padovan. Acetylcholinesterase inhibitors and depressive symptoms in patients with mild to moderate Alzheimer's disease. Aging clinical and experimental research. vol 19. issue 3. 2007-07-26. PMID:17607090. |
acetylcholinesterase inhibitors and depressive symptoms in patients with mild to moderate alzheimer's disease. |
2007-07-26 |
2023-08-12 |
Not clear |
| Luca Rozzini, Barbara Vicini Chilovi, Erik Bertoletti, Marco Trabucchi, Alessandro Padovan. Acetylcholinesterase inhibitors and depressive symptoms in patients with mild to moderate Alzheimer's disease. Aging clinical and experimental research. vol 19. issue 3. 2007-07-26. PMID:17607090. |
acetylcholinesterase inhibitor (acheis) therapy in alzheimer disease (ad) has been shown to provide cognitive benefits and to slow progression of the disease. |
2007-07-26 |
2023-08-12 |
Not clear |
| Kara A Bottiggi, Juan C Salazar, Lei Yu, Allison M Caban-Holt, Melody Ryan, Frederick A Schmit. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 15. issue 4. 2007-07-16. PMID:17384320. |
concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in alzheimer disease. |
2007-07-16 |
2023-08-12 |
Not clear |
| Norman R Relki. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease. Expert review of neurotherapeutics. vol 7. issue 6. 2007-07-03. PMID:17561789. |
beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in alzheimer's disease. |
2007-07-03 |
2023-08-12 |
Not clear |
| Norman R Relki. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease. Expert review of neurotherapeutics. vol 7. issue 6. 2007-07-03. PMID:17561789. |
acetylcholinesterase inhibitors (acheis) are generally regarded as palliative treatments for alzheimer's disease that slow the progression of dementia symptoms without altering alzheimer's disease's underlying pathogenic mechanisms. |
2007-07-03 |
2023-08-12 |
Not clear |
| Siriporn Chattipakorn, Anucha Pongpanparadorn, Wasana Pratchayasakul, Anchalee Pongchaidacha, Kornkanok Ingkaninan, Nipon Chattipakor. Tabernaemontana divaricata extract inhibits neuronal acetylcholinesterase activity in rats. Journal of ethnopharmacology. vol 110. issue 1. 2007-06-27. PMID:17023131. |
the current pharmacotherapy for alzheimer's disease (ad) is the use of acetylcholinesterase inhibitors (ache-is). |
2007-06-27 |
2023-08-12 |
rat |
| Alexis Kays Leonard, Anthony P Sileno, Gordon C Brandt, Charles A Foerder, Steven C Quay, Henry R Costantin. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. International journal of pharmaceutics. vol 335. issue 1-2. 2007-06-22. PMID:17174048. |
the purpose of the current investigation was to optimize an intranasal (in) galantamine (an acetylcholinesterase inhibitor used for treatment of alzheimer's disease) formulation using an in vitro tissue model, to correlate those results to in vivo bioavailability, and to compare emetic response to oral dosing. |
2007-06-22 |
2023-08-12 |
human |
| Pulok K Mukherjee, Venkatesan Kumar, Mainak Mal, Peter J Houghto. Acetylcholinesterase inhibitors from plants. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 14. issue 4. 2007-05-31. PMID:17346955. |
inhibition of acetylcholinesterase (ache), the key enzyme in the breakdown of acetylcholine, is considered as a promising strategy for the treatment of neurological disorders such as alzheimer's disease, senile dementia, ataxia and myasthenia gravis. |
2007-05-31 |
2023-08-12 |
Not clear |
| Elena I Solntseva, Julia V Bukanova, Evgeny Marchenko, Vladimir G Skrebitsk. Donepezil is a strong antagonist of voltage-gated calcium and potassium channels in molluscan neurons. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP. vol 144. issue 4. 2007-05-24. PMID:17126610. |
donepezil is an acetylcholinesterase inhibitor used in alzheimer's disease therapy. |
2007-05-24 |
2023-08-12 |
Not clear |
| M D Campanozzi, E Casali, F Neviani, E Martini, M Ner. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl). Archives of gerontology and geriatrics. vol 44 Suppl 1. 2007-05-18. PMID:17317439. |
evaluation of the slopes of cognitive impairment and disability in alzheimer's disease (ad) patients treated with acetylcholinesterase inhibitors (achel). |
2007-05-18 |
2023-08-12 |
human |
| Tadanobu Utsuki, Nao Uchimura, Mitsuru Irikura, Hiroshi Moriuchi, Harold W Holloway, Qian-Sheng Yu, Edward L Spangler, Jacek Mamczarz, Donald K Ingram, Tetsumi Irie, Nigel H Grei. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. The Journal of pharmacology and experimental therapeutics. vol 321. issue 1. 2007-05-14. PMID:17255466. |
phenserine (ps) was designed as a selective acetylcholinesterase (ache) inhibitor, with a tartrate form (pst) for oral administration in mild to moderate alzheimer's disease (ad). |
2007-05-14 |
2023-08-12 |
mouse |
| Kristin Huse Haug, Trond Myhrer, Frode Fonnu. The combination of donepezil and procyclidine protects against soman-induced seizures in rats. Toxicology and applied pharmacology. vol 220. issue 2. 2007-05-14. PMID:17289099. |
in this study, we have evaluated donepezil hydrochloride, a partial reversible inhibitor of acetylcholinesterase (ache) clinically used for treating alzheimer's disease, in combination with procyclidine, used in treatment of parkinson's disease and schizophrenia, as prophylaxis against intoxication by the nerve agent soman. |
2007-05-14 |
2023-08-12 |
rat |
| Marco Pugliese, Carlo Gangitano, Sabrina Ceccariglia, Josep Lluís Carrasco, Aurora Del Fà, Manuel José Rodríguez, Fabrizio Michetti, Joan Mascort, Nicole Mah. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes. Brain research. vol 1139. 2007-05-08. PMID:17292335. |
by using the canine counterpart of senile dementia of the alzheimer's type, a promising model of human brain aging and early phases of alzheimer's disease, we investigated how cerebellar pathology and acetylcholinesterase density could be related with cognitive dysfunction. |
2007-05-08 |
2023-08-12 |
human |
| Seok-Jong Suh, Byung-Soo Koo, Un-Ho Jin, Moon-Je Hwang, In-Seon Lee, Cheorl-Ho Ki. Pharmacological characterization of orally active cholinesterase inhibitory activity of Prunus persica L. Batsch in rats. Journal of molecular neuroscience : MN. vol 29. issue 2. 2007-04-02. PMID:16954599. |
prunus persica l. batsch water extract (ppe) is a potent acetylcholinesterase (ache) inhibitor screened for the treatment of alzheimer's disease. |
2007-04-02 |
2023-08-12 |
rat |
| Sylvie Chouinard, Emmanuel Stip, Julie Poulin, Jean-Pierre Melun, Roger Godbout, François Guillem, Henri Cohe. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Current medical research and opinion. vol 23. issue 3. 2007-03-30. PMID:17355738. |
acetylcholinesterase (ache) inhibitors, such as rivastigmine, have been shown to improve cognition in other disorders, particularly alzheimer's disease. |
2007-03-30 |
2023-08-12 |
Not clear |
| Lisa M Eubanks, Claude J Rogers, Albert E Beuscher, George F Koob, Arthur J Olson, Tobin J Dickerson, Kim D Jand. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Molecular pharmaceutics. vol 3. issue 6. 2007-03-26. PMID:17140265. |
here, we demonstrate that the active component of marijuana, delta9-tetrahydrocannabinol (thc), competitively inhibits the enzyme acetylcholinesterase (ache) as well as prevents ache-induced amyloid beta-peptide (abeta) aggregation, the key pathological marker of alzheimer's disease. |
2007-03-26 |
2023-08-12 |
Not clear |
| Silvia C Lenzken, Cristina Lanni, Stefano Govoni, Adele Lucchelli, Gennaro Schettini, Marco Racch. Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chemico-biological interactions. vol 165. issue 2. 2007-03-13. PMID:17196952. |
current therapies for alzheimer's disease treatment rely mainly on acetylcholinesterase inhibitors, improving central cholinergic neurotransmission. |
2007-03-13 |
2023-08-12 |
Not clear |